Publication | Closed Access

Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/TCRγδ+) and DERL-7 (CD56+/CD3−/TCRγδ−), derived from a single patient with CD56+ non-Hodgkin's lymphoma

Lymphoid NeoplasiaCd56+ Non-hodgkinImmunodeficienciesImmunologyTumor ImmunityPathologyImmune RegulationImmune SurveillanceNovel Cell LinesAdult T-cell Leukemia-lymphomaMedicineCell BiologyTumor BiologySingle Patient